Early View Articles

New tools - NOD ES cells, by Nick Holmes and Anne Cooke

Pathogenic mechanisms in type 1 diabetes, by Kate L. Graham, Robyn M. Sutherland, Stuart I. Mannering, Yuxing Zhao, Jonathan Chee, Balasubramanian Krishnamurthy, Helen E. Thomas, Andrew M Lew, Thomas WH Kay

Novel biomarkers in T1D, by Yulan Jinand and Jin-Xiong She

Gut microbiota and type 1 diabetes, by Outi Vaarala

Type 1 diabetes therapy beyond T cell targeting: monocytes, B cells, and innate lymphocytes, by F. Susan Wong and Li Wen

Tolerance Strategies Employing Antigen-Coupled Apoptotic Cells and Carboxylated PLG Nanoparticles for the Treatment of Type 1 Diabetes, by Suchitra Prasad, Dan Xu, and Stephen D. Miller

The clinical potential of antigen-specific therapies in type 1 diabetes – Experience from the Novo Nordisk T1D R&D Center, by Ken T. Coppieters, Birgit Sehested Hansen, Matthias G. von Herrath

In Vivo Delivery of Nucleic Acid-Formulated Microparticles as a Potential Tolerogenic Vaccine for the Treatment of Type 1 Diabetes, by Valentina Di Caro, Nick Giannoukakis, Massimo Trucco

Immune-Directed Therapy for Type 1 Diabetes at the Clinical Level: 2012 Update on the Immune Tolerance Network (ITN) Experience, by Mario R. Ehlers and Gerald T. Nepom

CD3 Monoclonal Antibodies in Type 1 Diabetes: A First Step Towards Operational Immune Tolerance in the Clinic, by Lucienne Chatenoud and Herman Waldman

Islet Transplantation in type 1 diabetes, by A.M. James Shapiro

Islet neogenesis: a possible pathway for beta-cell replenishment, by Susan Bonner-Weir, Lili Guo, Wan-Chun Li, Limor Ouziel-Yahalom, Philippe Lysy, Gordon C. Weir, Arun Sharma